Form 4: Galectin Therapeutics Director Gilbert S. Omenn Acquires 60,000 Stock Options
SEC Form 4 Filing
Director Gilbert S. Omenn reports acquisition of 60,000 stock options in Galectin Therapeutics, Inc.
Summary
- Gilbert S. Omenn, a director of Galectin Therapeutics Inc., filed a Form 4 with the SEC.
- The report details the acquisition of 60,000 stock options on January 23, 2025, at an exercise price of $1.23.
- These options, granted under the company's 2019 Omnibus Equity Incentive Plan, vest 100% on December 31, 2025.
- Following the transaction, Omenn directly owns 60,000 derivative securities.
Sentiment
Score: 5
Explanation: Neutral. This is a standard regulatory filing indicating insider activity. It doesn't inherently suggest positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market regarding insider activity.
Stakeholder Impact
- Shareholders may be interested in insider transactions as an indicator of management's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 01/23/2025 | Date of transaction: acquisition of stock options. |
| 01/23/2025 | Date of grant of stock options. |
| 12/31/2025 | Vesting date for the stock options. |
| 01/23/2035 | Expiration date for the stock options. |
| 01/27/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.